ASP Isotopes’ (ASPI) “Buy” Rating Reaffirmed at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of ASP Isotopes (NASDAQ:ASPI) in a research note published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a $11.00 target price on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, ASP Isotopes presently has an average rating of “Hold” and an average target price of $13.00.

ASP Isotopes Stock Down 1.2%

Shares of NASDAQ:ASPI opened at $5.00 on Tuesday. The stock’s 50-day moving average price is $5.08 and its 200-day moving average price is $6.79. ASP Isotopes has a 12-month low of $3.92 and a 12-month high of $14.49. The stock has a market capitalization of $629.50 million, a P/E ratio of -2.34 and a beta of 3.59. The company has a current ratio of 6.14, a quick ratio of 6.10 and a debt-to-equity ratio of 1.04.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings data on Friday, April 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.70). ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 307.82%. The company had revenue of $33.32 million for the quarter, compared to the consensus estimate of $2.03 million. On average, equities analysts anticipate that ASP Isotopes will post -0.24 earnings per share for the current year.

Insider Activity

In related news, COO Robert Ainscow sold 25,000 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $4.51, for a total value of $112,750.00. Following the sale, the chief operating officer directly owned 1,512,817 shares of the company’s stock, valued at $6,822,804.67. This trade represents a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.40% of the stock is owned by insiders.

Institutional Trading of ASP Isotopes

Several large investors have recently modified their holdings of the business. Alyeska Investment Group L.P. grew its stake in shares of ASP Isotopes by 73.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock worth $26,191,000 after purchasing an additional 2,072,851 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock worth $43,451,000 after purchasing an additional 1,241,024 shares during the last quarter. Rovida Investment Management Ltd grew its stake in shares of ASP Isotopes by 28.1% in the fourth quarter. Rovida Investment Management Ltd now owns 4,100,000 shares of the company’s stock worth $21,894,000 after purchasing an additional 900,000 shares during the last quarter. UBS Group AG grew its stake in shares of ASP Isotopes by 150.3% in the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock worth $12,875,000 after purchasing an additional 1,445,165 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of ASP Isotopes by 28.0% in the fourth quarter. Geode Capital Management LLC now owns 2,384,066 shares of the company’s stock worth $12,758,000 after purchasing an additional 521,611 shares during the last quarter. 16.80% of the stock is owned by institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.